Answer
Bosutinib can cause severe skin reactions such as Stevens–Johnson syndrome and toxic epidermal necrolysis, and should be permanently discontinued in patients who experience a severe skin reaction during treatment.
Sources for this answer
- Bosutinib 100 mg film-coated tabletsDr. Reddy's Laboratories (UK) Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 2Document updated
Sources checked